Vaxdyn

Bionaturis Group takes part in the BIOMAP project

BIOMAP is a consortium led by Laboratories Rovy  that includes Vivacell Biotechnology Spain, Vaxdyn,  and Bionaturis
The Feder-Interconecta Programme, via the Centre for the Development of Industrial Technology (CDTI, in Spanish), has granted Bionaturis 572.988€ for this biomedicine development initiative.

Jerez de la Frontera, January 12nd 2016. Bionaturis Group will take part in the BIOMAP consortium, devoted to the multivariate design of assays, with the ultimate goal of developing biomedicines using the pharmaceutical criteria for quality, security and efficacy designs (Quality by design or QbD).

The QbD method will be applied to the candidate selection processes for the development portfolio of each company in the consortium, reducing time and optimizing the process. In addition, these innovations aim to position the companies both technologically and commercially by providing the market with the scale-up system for structurally complex and highly-powerful biologics that will be both time and cost competitive.

The BIOMAP consortium is led by Laboratories Rovi and includes Vaxdyn, Vivacell Biotechnology Spain, and Bionaturis. In particular, Bionaturis will receive an incentive of 572.988€ granted by the CDTI from the Feder-Interconecta Programme, with the support of the Ministry of Economy and Competitiveness.

About Bionaturis

Bionaturis Group offers cutting-edge biotechnological drugs and services for human and animal health. Considered an international benchmark in vaccines research, the biotechnological Group which envisions a global access to health is listed on the Spanish stock exchange for SMEs (ticker BNT).

www.bionaturis.com

TO DOWNLOAD THE PRESS RELEASE, PLEASE, CLICK HERE

 

For further information:

Bionaturis Press

Virginia Montero

+34 856 818 424 / 655 311047

press@bionaturis.com

 

Disclaimer

The Market and investors are informed that the Company’s new developments are subject to significant risks and uncertainties, that include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate […]

January 12th, 2016|Blog english, Press Releases|Comments Off|

Bionaturis seeks solutions to antibiotic resistance

Bionaturis, a biotechnology company listing at the Spanish MAB, participates in the public-private consortium ADELIS, led by Laboratorios Rovi and involving, besides Bionaturis, the companies Biomedal, Vaxdyn, Althia, and research groups from Virgen del Rocio Hospital, University of Granada, University of Sevilla, University of Cadiz and, Genyo[1] as well. The project, which aims to an overall optimization of drug delivery systems, will last two years and will involve an estimated 2.6 million € global investment. The initiative is funded by the FEDER-INNTERCONECTA program, coordinated by The Centre for Industrial Technological Development (CDTI, in Spanish).

The activities and goals of Bionaturis within the project are framed in the seek for alternative solutions to the use of traditional antibiotics and tackling the alarming growth of antibacterial resistance. The emergence of multi-resistant bacterial strains is a growing problem of great concern for international health authorities. According to World Health Organization (WHO), a phenomena of resistance appears in 20% of patients treated for tuberculosis and are causing the majority of nosocomial infections acquired in hospitals, leading to more than 300,000 deaths annually in Europe and USA.

From animals to people

The problem is also transferred to animal health. New York Times has recently published a study showing that a majority of 30 antibiotics used in animal feed are linked to the increase of the phenomena of resistance in humans. Bionaturis addresses the problem by a pioneering approach proposing a collection of antimicrobial peptides (AMPs), some of them produced by the FLYLIFE system. Along the project, those AMPs will be tested in animal models using cutting-edge drug delivery systems originated from ADELIS. As a final outcome Bionaturis expects to obtain efficacy and safety data of the tested AMPs in mice models.

Juan José […]

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR